Research Output per year
Fingerprint Dive into the research topics where Roberto Gulminetti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 47 Similar Profiles
HIV
Medicine & Life Sciences
HIV-1
Medicine & Life Sciences
Hepacivirus
Medicine & Life Sciences
Genotype
Medicine & Life Sciences
Virus Diseases
Medicine & Life Sciences
Antiviral Agents
Medicine & Life Sciences
Ritonavir
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1991 2019
- 705 Citations
- 16 h-Index
- 55 Article
Lipid profile improvement in virologically suppressed hiv-1-infected patients switched to dolutegravir/ abacavir/lamivudine: Data from the SCOLTA project
Bagella, P., Squillace, N., Ricci, E., Gulminetti, R., De Socio, G. V., Taramasso, L., Pellicanò, G., Menzaghi, B., Celesia, B. M., Dentone, C., Orofino, G., Bonfanti, P. & Madeddu, G., Jan 1 2019, In : Infection and Drug Resistance. 12, p. 1385-1391 7 p.Research output: Contribution to journal › Article
Open Access
Lipids
Protease Inhibitors
Reverse Transcriptase Inhibitors
Triglycerides
HDL Cholesterol
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy
DAU Study Group, Jun 1 2019, In : AIDS (London, England). 33, 7, p. 1256-1260 5 p.Research output: Contribution to journal › Article
Viral Load
HIV-1
Reverse Transcriptase Inhibitors
Cardiovascular Diseases
HIV
Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
Paolucci, S., Novazzi, F., Piralla, A., Maserati, R., Gulminetti, R., Novati, S., Barbarini, G., Sacchi, P., Fratini, A., Bellotti, L. & Baldanti, F., Jan 1 2019, In : Infection and Drug Resistance. 12, p. 1975-1984 10 p.Research output: Contribution to journal › Article
Open Access
Hepacivirus
Antiviral Agents
Genotype
RNA
Treatment Failure
5
Citations
(Scopus)
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)
on behalf of CISAI Study Group, Jul 31 2018, In : BMC Infectious Diseases. 18, 1, 357.Research output: Contribution to journal › Article
Rilpivirine
efavirenz
Integrase Inhibitors
Ritonavir
Protease Inhibitors
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA)
Taramasso, L., Tatarelli, P., Ricci, E., Madeddu, G., Menzaghi, B., Squillace, N., De Socio, G. V., Martinelli, C., Gulminetti, R., Maggi, P., Orofino, G., Vichi, F., Di Biagio, A., Bonfanti, P., Bellacosa, C., Calza, L., Abeli, C., Celesia, B. M., Grosso, C., Stagno, A. & 26 others, , Jul 31 2018, In : BMC Infectious Diseases. 18, 1, p. 357Research output: Contribution to journal › Article